Request Demo
Last update 25 Aug 2025
CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Last update 25 Aug 2025
Overview
Basic Info
Drug Type CAR-NK |
Synonyms C9/CD5CAR/IL-15 NK cells(The University of Texas MD Anderson Cancer Center), CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells, iC9/CD5CAR/IL-15 NK cells(The University of Texas MD Anderson Cancer Center) |
Target |
Action agonists, inhibitors |
Mechanism IL15R agonists(Interleukin-15 receptors agonists), T-cell surface glycoprotein CD5 inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)NCT07137481
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
NCT05110742
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
100 Clinical Results associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Translational Medicine associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Patents (Medical) associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
100 Deals associated with CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | United States | 28 Feb 2026 | |
| Prolymphocytic Leukemia | Phase 2 | United States | 28 Feb 2026 | |
| Mantle cell lymphoma refractory | Phase 2 | United States | 22 Apr 2024 | |
| Mixed phenotype acute leukemia | Phase 2 | United States | 22 Apr 2024 | |
| Richter's syndrome | Phase 2 | United States | 22 Apr 2024 | |
| Small Lymphocytic Lymphoma | Phase 2 | United States | 22 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free